J&J: scientific breakthrough to treat dengue
(CercleFinance.com) - Johnson & Johnson's Janssen Pharmaceuticals yesterday announced the publication of new data in the journal Nature showing that an early-stage compound with a novel mechanism of action could potentially treat all serotypes of dengue fever and provide a period of protection against dengue virus acquisition.
Janssen is now moving its dengue program into clinical development.
"Data from the early-stage study suggest that an antiviral compound prevents the interaction between two viral proteins (NS3 and NS4B) that play an important role in the replication process of a virus, thereby stopping the ability of the virus to reproduce," the group said.
"With no treatments available, dengue infects up to 400 million people each year and the pace of outbreaks is increasing," it added.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Janssen is now moving its dengue program into clinical development.
"Data from the early-stage study suggest that an antiviral compound prevents the interaction between two viral proteins (NS3 and NS4B) that play an important role in the replication process of a virus, thereby stopping the ability of the virus to reproduce," the group said.
"With no treatments available, dengue infects up to 400 million people each year and the pace of outbreaks is increasing," it added.
Copyright (c) 2021 CercleFinance.com. All rights reserved.